These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 38027027)

  • 1. Metabolic dysfunction-associated steatotic liver disease: ferroptosis related mechanisms and potential drugs.
    Zhu B; Wei Y; Zhang M; Yang S; Tong R; Li W; Long E
    Front Pharmacol; 2023; 14():1286449. PubMed ID: 38027027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic-Dysfunction-Associated Steatotic Liver Disease-Its Pathophysiology, Association with Atherosclerosis and Cardiovascular Disease, and Treatments.
    Yanai H; Adachi H; Hakoshima M; Iida S; Katsuyama H
    Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37895151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathology and Pathogenesis of Metabolic Dysfunction-Associated Steatotic Liver Disease-Associated Hepatic Tumors.
    Takahashi Y; Dungubat E; Kusano H; Fukusato T
    Biomedicines; 2023 Oct; 11(10):. PubMed ID: 37893134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Metabolic Dysfunction-Associated Steatotic Liver Disease/Non-alcoholic Fatty Liver Disease With Type 2 Diabetes Mellitus: A Case-Control Study in a Tertiary Care Hospital in Pakistan.
    Zahoor F; Saeed NU; Javed S; Sadiq HZ; Mand Khan F; Haider M; Shafqat MN; Maqbool A; Chaudhry A
    Cureus; 2023 Oct; 15(10):e47240. PubMed ID: 38021965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Roles of Activin A and Gpnmb in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
    Liu H; Yerevanian A; Westerhoff M; Hastings MH; Guerra JRB; Zhao M; Svensson KJ; Cai B; Soukas AA; Rosenzweig A
    Diabetes; 2024 Feb; 73(2):260-279. PubMed ID: 37934943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Familial coaggregation of MASLD with hepatocellular carcinoma and adverse liver outcomes: Nationwide multigenerational cohort study.
    Ebrahimi F; Hagström H; Sun J; Bergman D; Shang Y; Yang W; Roelstraete B; Ludvigsson JF
    J Hepatol; 2023 Dec; 79(6):1374-1384. PubMed ID: 37647992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploring the landscape of steatotic liver disease in the general US population.
    Ciardullo S; Carbone M; Invernizzi P; Perseghin G
    Liver Int; 2023 Nov; 43(11):2425-2433. PubMed ID: 37592856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Natural history of metabolic dysfunction-associated steatotic liver disease.
    Lekakis V; Papatheodoridis GV
    Eur J Intern Med; 2024 Apr; 122():3-10. PubMed ID: 37940495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating hormones in biopsy-proven steatotic liver disease and steatohepatitis: A Multicenter Observational Study.
    Valenzuela-Vallejo L; Chrysafi P; Kouvari M; Guatibonza-Garcia V; Mylonakis SC; Katsarou A; Verrastro O; Markakis G; Eslam M; Papatheodoridis G; Mingrone G; George J; Mantzoros CS
    Metabolism; 2023 Nov; 148():155694. PubMed ID: 37757973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-the-Art Review.
    Chan WK; Chuah KH; Rajaram RB; Lim LL; Ratnasingam J; Vethakkan SR
    J Obes Metab Syndr; 2023 Sep; 32(3):197-213. PubMed ID: 37700494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Associations between metabolic hyperferritinaemia, fibrosis-promoting alleles and clinical outcomes in steatotic liver disease.
    Suresh D; Li A; Miller MJ; Wijarnpreecha K; Chen VL
    Liver Int; 2024 Feb; 44(2):389-398. PubMed ID: 37971775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The association between metabolic dysfunction-associated steatotic liver disease, cardiovascular and cerebrovascular diseases and the thickness of carotid plaque.
    Huang Y; Wang Y; Xiao Z; Yao S; Tang Y; Zhou L; Wang Q; Xie Y; Zhang L; Zhou Y; Lu Y; Zhu W; Chen M
    BMC Cardiovasc Disord; 2023 Nov; 23(1):554. PubMed ID: 37951879
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulin resistance and central obesity determine hepatic steatosis and explain cardiovascular risk in steatotic liver disease.
    Semmler G; Balcar L; Wernly S; Völkerer A; Semmler L; Hauptmann L; Wernly B; Aigner E; Niederseer D; Datz C
    Front Endocrinol (Lausanne); 2023; 14():1244405. PubMed ID: 37842290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of an Eight Week Very Low-Calorie Ketogenic Diet (VLCKD) on White Blood Cell and Platelet Counts in Relation to Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Subjects with Overweight and Obesity.
    De Nucci S; Bonfiglio C; Donvito R; Di Chito M; Cerabino N; Rinaldi R; Sila A; Shahini E; Giannuzzi V; Pesole PL; Coletta S; Lanzilotta E; Piazzolla G; Cozzolongo R; Giannelli G; De Pergola G
    Nutrients; 2023 Oct; 15(20):. PubMed ID: 37892542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolomic Phenotype of Hepatic Steatosis and Fibrosis in Mexican Children Living with Obesity.
    Garibay-Nieto N; Pedraza-Escudero K; Omaña-Guzmán I; Garcés-Hernández MJ; Villanueva-Ortega E; Flores-Torres M; Pérez-Hernández JL; León-Hernández M; Laresgoiti-Servitje E; Palacios-González B; López-Alvarenga JC; Lisker-Melman M; Vadillo-Ortega F
    Medicina (Kaunas); 2023 Oct; 59(10):. PubMed ID: 37893503
    [No Abstract]   [Full Text] [Related]  

  • 16. The Lasting Effects of COVID-19 on the Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
    Backer S; Khanna D
    Cureus; 2023 Sep; 15(9):e45231. PubMed ID: 37842470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The multifaceted role of ferroptosis in liver disease.
    Chen J; Li X; Ge C; Min J; Wang F
    Cell Death Differ; 2022 Mar; 29(3):467-480. PubMed ID: 35075250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The ubiquitin-like modifier FAT10 is induced in MASLD and impairs the lipid-regulatory activity of PPARα.
    Clavreul L; Bernard L; Cotte AK; Hennuyer N; Bourouh C; Devos C; Helleboid A; Haas JT; Verrijken A; Gheeraert C; Derudas B; Guille L; Chevalier J; Eeckhoute J; Vallez E; Dorchies E; Van Gaal L; Lassailly G; Francque S; Staels B; Paumelle R
    Metabolism; 2024 Feb; 151():155720. PubMed ID: 37926201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liver biopsy-based validation, confirmation and comparison of the diagnostic performance of established and novel non-invasive steatotic liver disease indexes: Results from a large multi-center study.
    Kouvari M; Valenzuela-Vallejo L; Guatibonza-Garcia V; Polyzos SA; Deng Y; Kokkorakis M; Agraz M; Mylonakis SC; Katsarou A; Verrastro O; Markakis G; Eslam M; Papatheodoridis G; George J; Mingrone G; Mantzoros CS
    Metabolism; 2023 Oct; 147():155666. PubMed ID: 37527759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frontiers of Collaboration between Primary Care and Specialists in the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease: A Review.
    Nagai K; Nagai K; Iwaki M; Kobayashi T; Nogami A; Oka M; Saito S; Yoneda M
    Life (Basel); 2023 Oct; 13(11):. PubMed ID: 38004284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.